[Heparin, low molecular weight heparin, heparinoid, and antithrombin III therapy of disseminated intravascular coagulation].
Pathophysiology of DIC varies with underlining diseases but its precipitating factor is accepted to be mainly as an accerelation of blood coagulation. From these back grounds it is indicated that the removal of the original pathogenetic factor is important as the first step of treatment, and at the same time the anticoagulant treatment has been also advised as a fundamental remedy against this disease state. For this purpose, heparin, low molecular weight heparin, heparinoid, or antithrombin III has been used so far on the clinical practice. However their beneficial effects or efficasies have not been established yet. This paper reports the pharmacological properties of these anticoagulants and some data of their clinical evaluations.
Nakagawa
M
M
Second Department of Medicine, Kyoto Prefectural University of Medicine.
D000990:Antithrombin III / Q000627:therapeutic use*; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy*; D006493:Heparin / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006496:Heparinoids / Q000627:therapeutic use*; D006801:Humans
D006495:Heparin, Low-Molecular-Weight; D006496:Heparinoids; D000990:Antithrombin III; D006493:Heparin